BlueRock Therapeutics is an anti-aging company dedicated to developing cell therapies to combat degenerative diseases. By utilizing pluripotent stem cells, they aim to replace damaged or lost cells, restoring function and improving patients’ quality of life. Their primary goal is to revolutionize medical treatment, making significant strides in regenerative medicine.
The following is their official mission statement:
Our mission is to discover and develop cell therapies that can change the way we treat disease and improve the lives of patients.
Feel welcome to share your own thoughts on this company in the comment section below as well. I will be happy to discuss and learn more about how you see their potential in this field.
The Solution
Overall BlueRock Therapeutics is looking to find a solution that not just treats disease symptoms, but can restore function by replacing lost or damaged cells. Allowing patients to get rid of lifelong drug treatment regimens, and instead be offered a treatment that not only prevents symptoms but addresses them at their source.
Parkinson’s Disease
BlueRock Therapeutics’ flagship program focuses on developing a cell therapy for advanced Parkinson’s disease. The flagship candidate is named bemdaneprocel. This approach involves generating dopaminergic neurons from pluripotent stem cells to replace those lost due to the disease. These neurons are intended to restore the brain’s dopamine levels, which can significantly improve motor functions and quality of life for patients.
Results from their phase 1 clinical trial has indicated safety and efficacy. It was recently announced that BlueRock Therapeutics received the FDA Regenerative Medicine Advanced Therapy designation for their Parkinson’s disease cell therapy candidate bemdaneprocel. This is very exciting news, and it will be interesting to follow the further development. According to the company phase 2 trials are already being planned.
You can read more about the phase 1 clinical trials here.
Retinal Diseases
In the field of ophthalmology, BlueRock is advancing therapies to address retinal diseases such as age-related macular degeneration and retinitis pigmentosa. Using their cell therapy platform, they aim to replace damaged retinal cells, potentially restoring vision for patients suffering from these debilitating conditions. This particular approach could provide a much needed alternative to existing treatments, which often only slow disease progression rather than restore lost vision. The company currently has three candidates in this field, all of which are in preclinical trials.
Cardiac Therapy
Another area of research at BlueRock is cardiac therapy. By generating cardiomyocytes from stem cells, they aim to repair heart tissue damaged by myocardial infarction or other cardiac diseases. This therapy has the potential to restore heart function, reduce symptoms, and improve the overall prognosis for patients with heart conditions. The company’s candidate is named BR-CM01, and is currently in preclinical trials.
The Company
BlueRock Therapeutics was founded in 2016, and is headquartered in Cambridge, Massachusetts. The CEO of the company is Seth Ettenberg.
BlueRock Therapeutics is a wholly owned independently operated subsidiary of Bayer AG. As such we know that there is a lot of muscle behind this company, and that, if considered a business priority, they will most definitely have the capital needed to progress with any clinical programs.
The company has formed strategic partnerships to bolster its innovative efforts. In particular they highlight their collaboration with FUJIFILM Cellular Dynamics and Opsis Therapeutics to license and develop cell therapy candidates for treating primary photoreceptor diseases. Additionally, BlueRock has partnered with the Foundation Fighting Blindness to expand the Uni-Rare natural history study of inherited retinal diseases.
Read about more anti-aging companies on this website through this link.
